An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections.

Animals Antibodies, Monoclonal, Humanized / pharmacology Antibodies, Neutralizing / pharmacology Antiviral Agents / pharmacology HEK293 Cells Hendra Virus / drug effects Henipavirus Infections / drug therapy Humans Models, Molecular Nipah Virus / drug effects Viral Fusion Proteins / antagonists & inhibitors Virus Internalization / drug effects

Journal

Nature structural & molecular biology
ISSN: 1545-9985
Titre abrégé: Nat Struct Mol Biol
Pays: United States
ID NLM: 101186374

Informations de publication

Date de publication:
10 2019
Historique:
received: 09 08 2019
accepted: 21 08 2019
pubmed: 2 10 2019
medline: 12 2 2020
entrez: 2 10 2019
Statut: ppublish

Résumé

Nipah virus (NiV) and Hendra virus (HeV) are zoonotic henipaviruses (HNVs) responsible for outbreaks of encephalitis and respiratory illness with fatality rates of 50-100%. No vaccines or licensed therapeutics currently exist to protect humans against NiV or HeV. HNVs enter host cells by fusing the viral and cellular membranes via the concerted action of the attachment (G) and fusion (F) glycoproteins, the main targets of the humoral immune response. Here, we describe the isolation and humanization of a potent monoclonal antibody cross-neutralizing NiV and HeV. Cryo-electron microscopy, triggering and fusion studies show the antibody binds to a prefusion-specific quaternary epitope, conserved in NiV F and HeV F glycoproteins, and prevents membrane fusion and viral entry. This work supports the importance of the HNV prefusion F conformation for eliciting a robust immune response and paves the way for using this antibody for prophylaxis and post-exposure therapy with NiV- and HeV-infected individuals.

Identifiants

DOI: 10.1038/s41594-019-0308-9 PMID: 31570878 PMC: PMC6858553
pubmed: 31570878
doi: 10.1038/s41594-019-0308-9
pii: 10.1038/s41594-019-0308-9
pmc: PMC6858553
mid: NIHMS1537993
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antibodies, Neutralizing 0
Antiviral Agents 0
Viral Fusion Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

980-987

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM120553
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142764
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI054715
Pays : United States
Organisme : NIH HHS
ID : S10 OD021832
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201700059C
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI077995
Pays : United States

Références

Eaton, B. T., Broder, C. C., Middleton, D. & Wang, L. F. Hendra and Nipah viruses: different and dangerous. Nat. Rev. Microbiol. 4, 23–35 (2006).
pubmed: 16357858 doi: 10.1038/nrmicro1323
Beineke, A., Baumgartner, W. & Wohlsein, P. Cross-species transmission of canine distemper virus-an update. One Health 1, 49–59 (2015).
pubmed: 28616465 pmcid: 5462633 doi: 10.1016/j.onehlt.2015.09.002
Clayton, B. A., Wang, L. F. & Marsh, G. A. Henipaviruses: an updated review focusing on the pteropid reservoir and features of transmission. Zoonoses Public Health 60, 69–83 (2013).
pubmed: 22709528 doi: 10.1111/j.1863-2378.2012.01501.x
Broder, C. C., Weir, D. L. & Reid, P. A. Hendra virus and Nipah virus animal vaccines. Vaccine 34, 3525–3534 (2016).
pubmed: 27154393 pmcid: 4933500 doi: 10.1016/j.vaccine.2016.03.075
Luby, S. P. & Gurley, E. S. Epidemiology of Henipavirus disease in humans. Curr. Top. Microbiol. Immunol. 359, 25–40 (2012).
pubmed: 22752412
Arunkumar, G. et al. Outbreak investigation of Nipah virus disease in Kerala, India, 2018. J. Infect. Dis. 219, 1867–1878 (2018).
doi: 10.1093/infdis/jiy612
Pernet, O. et al. Evidence for henipavirus spillover into human populations in Africa. Nat. Commun. 5, 5342 (2014).
pubmed: 25405640 pmcid: 4237230 doi: 10.1038/ncomms6342
Wong, J. J. W. et al. Monomeric ephrinB2 binding induces allosteric changes in Nipah virus G that precede its full activation. Nat. Commun. 8, 781 (2017).
pubmed: 28974687 pmcid: 5626764 doi: 10.1038/s41467-017-00863-3
Xu, K. et al. Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc. Natl Acad. Sci. USA 105, 9953–9958 (2008).
pubmed: 18632560 doi: 10.1073/pnas.0804797105
Negrete, O. A. et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436, 401–405 (2005).
pubmed: 16007075 doi: 10.1038/nature03838
Bowden, T. A. et al. Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2. Nat. Struct. Mol. Biol. 15, 567–572 (2008).
pubmed: 18488039 doi: 10.1038/nsmb.1435
Bonaparte, M. I. et al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc. Natl Acad. Sci. USA 102, 10652–10657 (2005).
pubmed: 15998730 doi: 10.1073/pnas.0504887102
Xu, K. et al. Crystal structure of the pre-fusion nipah virus fusion glycoprotein reveals a novel hexamer-of-trimers assembly. PLoS Pathog. 11, e1005322 (2015).
pubmed: 26646856 pmcid: 4672880 doi: 10.1371/journal.ppat.1005322
Pager, C. T., Craft, W. W. Jr, Patch, J. & Dutch, R. E. A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L. Virology 346, 251–257 (2006).
pubmed: 16460775 doi: 10.1016/j.virol.2006.01.007
Pager, C. T. & Dutch, R. E. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J. Virol. 79, 12714–12720 (2005).
pubmed: 16188974 pmcid: 1235853 doi: 10.1128/JVI.79.20.12714-12720.2005
Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690–698 (2008).
pubmed: 18596815 pmcid: 2517140 doi: 10.1038/nsmb.1456
Chan, Y. P. et al. Biochemical, conformational and immunogenic analysis of soluble trimeric forms of Henipavirus fusion glycoproteins. J. Virol. 86, 11457–11471 (2012).
pubmed: 22915804 pmcid: 3486283 doi: 10.1128/JVI.01318-12
Liu, Q. et al. Unraveling a three-step spatiotemporal mechanism of triggering of receptor-induced Nipah virus fusion and cell entry. PLoS Pathog. 9, e1003770 (2013).
pubmed: 24278018 pmcid: 3837712 doi: 10.1371/journal.ppat.1003770
Connolly, S. A., Leser, G. P., Yin, H. S., Jardetzky, T. S. & Lamb, R. A. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc. Natl Acad. Sci. USA 103, 17903–17908 (2006).
pubmed: 17093041 doi: 10.1073/pnas.0608678103
Yin, H. S., Paterson, R. G., Wen, X., Lamb, R. A. & Jardetzky, T. S. Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc. Natl Acad. Sci. USA 102, 9288–9293 (2005).
pubmed: 15964978 doi: 10.1073/pnas.0503989102
Yin, H. S., Wen, X., Paterson, R. G., Lamb, R. A. & Jardetzky, T. S. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439, 38–44 (2006).
pubmed: 16397490 doi: 10.1038/nature04322
McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113–1117 (2013).
pubmed: 23618766 pmcid: 23618766 doi: 10.1126/science.1234914
McLellan, J. S., Yang, Y., Graham, B. S. & Kwong, P. D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85, 7788–7796 (2011).
pubmed: 21613394 pmcid: 21613394 doi: 10.1128/JVI.00555-11
Swanson, K. A. et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl Acad. Sci. USA 108, 9619–9624 (2011).
pubmed: 21586636 doi: 10.1073/pnas.1106536108
Griffin, D. E. Immune responses during measles virus infection. Curr. Top. Microbiol. Immunol. 191, 117–134 (1995).
pubmed: 7789155
Zhu, Z. et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197, 846–853 (2008).
pubmed: 18271743 doi: 10.1086/528801
Zhu, Z. et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80, 891–899 (2006).
pubmed: 16378991 pmcid: 1346873 doi: 10.1128/JVI.80.2.891-899.2006
Borisevich, V. et al. Escape from monoclonal antibody neutralization affects Henipavirus fitness in vitro and in vivo. J. Infect. Dis. 213, 448–455 (2016).
pubmed: 26357909 doi: 10.1093/infdis/jiv449
Bossart, K. N. et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog. 5, e1000642 (2009).
pubmed: 19888339 pmcid: 2765826 doi: 10.1371/journal.ppat.1000642
Bossart, K. N. et al. A neutralizing human monoclonal antibody protects african green monkeys from Hendra virus challenge. Sci. Transl. Med. 3, 105ra103 (2011).
pubmed: 22013123 pmcid: 3313625 doi: 10.1126/scitranslmed.3002901
Geisbert, T. W. et al. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci. Transl. Med. 6, 242ra82 (2014).
pubmed: 24964990 pmcid: 4467163 doi: 10.1126/scitranslmed.3008929
Mire, C. E. et al. Pathogenic differences between Nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy. Sci. Rep. 6, 30916 (2016).
pubmed: 27484128 pmcid: 4971471 doi: 10.1038/srep30916
Guillaume, V. et al. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J. Virol. 80, 1972–1978 (2006).
pubmed: 16439553 pmcid: 1367164 doi: 10.1128/JVI.80.4.1972-1978.2006
Guillaume, V. et al. Acute Hendra virus infection: analysis of the pathogenesis and passive antibody protection in the hamster model. Virology 387, 459–465 (2009).
pubmed: 19328514 doi: 10.1016/j.virol.2009.03.001
Broder, C. C. et al. Immunization strategies against henipaviruses. Curr. Top. Microbiol. Immunol. 359, 197–223 (2012).
pubmed: 22481140 pmcid: 4465348
Aguilar, H. C. et al. N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J. Virol. 80, 4878–4889 (2006).
pubmed: 16641279 pmcid: 1472062 doi: 10.1128/JVI.80.10.4878-4889.2006
Carter, J. R., Pager, C. T., Fowler, S. D. & Dutch, R. E. Role of N-linked glycosylation of the Hendra virus fusion protein. J. Virol. 79, 7922–7925 (2005).
pubmed: 15919949 pmcid: 1143676 doi: 10.1128/JVI.79.12.7922-7925.2005
Moll, M., Kaufmann, A. & Maisner, A. Influence of N-glycans on processing and biological activity of the Nipah virus fusion protein. J. Virol. 78, 7274–7278 (2004).
pubmed: 15194804 pmcid: 421684 doi: 10.1128/JVI.78.13.7274-7278.2004
Xu, K. et al. Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody. PLoS Pathog. 9, e1003684 (2013).
pubmed: 24130486 pmcid: 3795035 doi: 10.1371/journal.ppat.1003684
Lee, J. K., Prussia, A., Snyder, J. P. & Plemper, R. K. Reversible inhibition of the fusion activity of measles virus F protein by an engineered intersubunit disulfide bridge. J. Virol. 81, 8821–8826 (2007).
pubmed: 17553889 pmcid: 1951371 doi: 10.1128/JVI.00754-07
McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013).
pubmed: 24179220 pmcid: 24179220 doi: 10.1126/science.1243283
Wong, J. J., Paterson, R. G., Lamb, R. A. & Jardetzky, T. S. Structure and stabilization of the Hendra virus F glycoprotein in its prefusion form. Proc. Natl Acad. Sci. USA 113, 1056–1061 (2016).
pubmed: 26712026 doi: 10.1073/pnas.1523303113
Stewart-Jones, G. B. E. et al. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4. Proc. Natl Acad. Sci. USA 115, 12265–12270 (2018).
pubmed: 30420505 doi: 10.1073/pnas.1811980115
Bossart, K. N. et al. Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virol. J. 2, 57 (2005).
pubmed: 16026621 pmcid: 1208959 doi: 10.1186/1743-422X-2-57
Bossart, K. N. et al. Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J. Virol. 76, 11186–11198 (2002).
pubmed: 12388678 pmcid: 136767 doi: 10.1128/JVI.76.22.11186-11198.2002
Sastre, P., Melero, J. A., Garcia-Barreno, B. & Palomo, C. Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. J. Med. Virol. 76, 248–255 (2005).
pubmed: 15834867 doi: 10.1002/jmv.20349
Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).
pubmed: 26333350 pmcid: 26333350 doi: 10.1038/ncomms9143
Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420–1431.e17 (2019).
pubmed: 30849373 pmcid: 6424820 doi: 10.1016/j.cell.2019.01.046
Battles, M. B. et al. Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat. Commun. 8, 1528 (2017).
pubmed: 29142300 pmcid: 5688127 doi: 10.1038/s41467-017-01708-9
Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47–53 (2014).
pubmed: 25171469 pmcid: 4214273 doi: 10.1038/nature13777
Wec, A. Z. et al. Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection. Cell Host Microbe 25, 39–48.e5 (2019).
pubmed: 30629917 doi: 10.1016/j.chom.2018.12.004
Bornholdt, Z. A. et al. A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates. Cell Host Microbe 25, 49–58.e5 (2019).
pubmed: 30629918 doi: 10.1016/j.chom.2018.12.005
Rockx, B. et al. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J. Infect. Dis. 201, 946–955 (2010).
pubmed: 20144042 pmcid: 2826557 doi: 10.1086/651022
Debat, H. et al. Overpassing an aberrant Vκ gene to sequence an anti-idiotypic abzyme with β-lactamase-like activity that could have a linkage with autoimmune diseases. FASEB J. 15, 815–822 (2001).
pubmed: 11259400 doi: 10.1096/fj.00-0410com
Wang, Z. et al. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J. Immunol. Methods 233, 167–177 (2000).
pubmed: 10648866 doi: 10.1016/S0022-1759(99)00184-2
Zhu, Z. & Dimitrov, D. S. Construction of a large naive human phage-displayed Fab library through one-step cloning. Methods Mol. Biol. 525, 129–142 (2009).
pubmed: 19252833 pmcid: 3423197 doi: 10.1007/978-1-59745-554-1_6
Dimitrova, D., Choudhry, V. & Broder, C. C. Antibody fragment expression and purification. Methods Mol. Biol. 525, 491–498 (2009).
pubmed: 19252844 pmcid: 2858623 doi: 10.1007/978-1-59745-554-1_25
Chan, Y. P., Yan, L., Feng, Y. R. & Broder, C. C. Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery. Methods Mol. Biol. 525, 31–58 (2009).
pubmed: 19252850 pmcid: 3277858 doi: 10.1007/978-1-59745-554-1_2
Feng, Y. & Dimitrov, D. S. Scaling-up and production of therapeutic antibodies for preclinical studies. Methods Mol. Biol. 525, 499–508 (2009).
pubmed: 19252843 pmcid: 3402213 doi: 10.1007/978-1-59745-554-1_26
Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
pubmed: 2815665 pmcid: 2815665 doi: 10.1107/S0907444909047337
Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214 (2013).
pubmed: 23793146 pmcid: 23793146 doi: 10.1107/S0907444913000061
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 19461840 pmcid: 19461840
Walls, A. C. et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 176, 1026–1039.e15 (2019).
pubmed: 30712865 doi: 10.1016/j.cell.2018.12.028
Cowtan, K. The Buccaneer software for automated model building. 1. Tracing protein chains. Acta Crystallogr. D Biol. Crystallogr. 62, 1002–1011 (2006).
pubmed: 16929101 pmcid: 16929101 doi: 10.1107/S0907444906022116
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
pubmed: 20383002 pmcid: 20383002 doi: 10.1107/S0907444910007493
Blanc, E. et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D Biol. Crystallogr. 60, 2210–2221 (2004).
pubmed: 15572774 doi: 10.1107/S0907444904016427
Vagin, A. A. et al. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr. D Biol. Crystallogr. 60, 2184–2195 (2004).
pubmed: 15572771 doi: 10.1107/S0907444904023510
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010).
pubmed: 20057044 pmcid: 20057044 doi: 10.1107/S0907444909042073
Suloway, C. et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol. 151, 41–60 (2005).
pubmed: 15890530 pmcid: 15890530 doi: 10.1016/j.jsb.2005.03.010
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
pubmed: 28250466 pmcid: 5494038 doi: 10.1038/nmeth.4193
Voss, N. R., Yoshioka, C. K., Radermacher, M., Potter, C. S. & Carragher, B. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J. Struct. Biol. 166, 205–213 (2009).
pubmed: 19374019 pmcid: 2768396 doi: 10.1016/j.jsb.2009.01.004
Lander, G. C. et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95–102 (2009).
pubmed: 19263523 pmcid: 2775544 doi: 10.1016/j.jsb.2009.01.002
Zhang, K. Gctf: real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).
pubmed: 26592709 pmcid: 4711343 doi: 10.1016/j.jsb.2015.11.003
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife 7, e42166 (2018).
pubmed: 30412051 pmcid: 6250425 doi: 10.7554/eLife.42166
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
pubmed: 28165473 doi: 10.1038/nmeth.4169
Zivanov, J., Nakane, T. & Scheres, S. H. W. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ 6, 5–17 (2019).
pubmed: 30713699 pmcid: 6327179 doi: 10.1107/S205225251801463X
Scheres, S. H. & Chen, S. Prevention of overfitting in cryo-EM structure determination. Nat. Methods 9, 853–854 (2012).
pubmed: 22842542 pmcid: 22842542 doi: 10.1038/nmeth.2115
Rosenthal, P. B. & Henderson, R. Optimal determination of particle orientation, absolute hand and contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 333, 721–745 (2003).
pubmed: 14568533 pmcid: 14568533 doi: 10.1016/j.jmb.2003.07.013
Chen, S. et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24–35 (2013).
pubmed: 23872039 pmcid: 23872039 doi: 10.1016/j.ultramic.2013.06.004
Goddard, T. D., Huang, C. C. & Ferrin, T. E. Visualizing density maps with UCSF Chimera. J. Struct. Biol. 157, 281–287 (2007).
pubmed: 16963278 pmcid: 16963278 doi: 10.1016/j.jsb.2006.06.010
Brown, A. et al. Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions. Acta Crystallogr. D Biol. Crystallogr. 71, 136–153 (2015).
pubmed: 25615868 pmcid: 25615868 doi: 10.1107/S1399004714021683
DiMaio, F., Leaver-Fay, A., Bradley, P., Baker, D. & Andre, I. Modeling symmetric macromolecular structures in Rosetta3. PLoS One 6, e20450 (2011).
pubmed: 21731614 pmcid: 3120754 doi: 10.1371/journal.pone.0020450
DiMaio, F. et al. Atomic-accuracy models from 4.5-Å cryo-electron microscopy data with density-guided iterative local refinement. Nat. Methods 12, 361–365 (2015).
pubmed: 25707030 pmcid: 25707030 doi: 10.1038/nmeth.3286
Wang, R. Y. et al. Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta. Elife 5, e17219 (2016).
pubmed: 27669148 pmcid: 5115868 doi: 10.7554/eLife.17219
Frenz, B. et al. Automatically fixing errors in glycoprotein structures with Rosetta. Structure 27, 134–139 (2019).
pubmed: 30344107 doi: 10.1016/j.str.2018.09.006
Barad, B. A. et al. EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy. Nat. Methods 12, 943–946 (2015).
pubmed: 26280328 pmcid: 26280328 doi: 10.1038/nmeth.3541
Agirre, J. et al. Privateer: software for the conformational validation of carbohydrate structures. Nat. Struct. Mol. Biol. 22, 833–834 (2015).
pubmed: 26581513 pmcid: 26581513 doi: 10.1038/nsmb.3115
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
pubmed: 28710774 doi: 10.1002/pro.3235
Bossart, K. N. & Broder, C. C. Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol. Biol. 269, 309–332 (2004).
pubmed: 15114023
Broder, C. C. et al. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl Acad. Sci. USA 91, 11699–11703 (1994).
pubmed: 7972127 doi: 10.1073/pnas.91.24.11699
Ferrara, F. & Temperton, N. Pseudotype neutralization assays: from laboratory bench to data analysis. Methods Protoc. 1, 8 (2018).
pmcid: 6526431 doi: 10.3390/mps1010008 pubmed: 6526431

Auteurs

Ha V Dang (HV)

Department of Biochemistry, University of Washington, Seattle, WA, USA.

Yee-Peng Chan (YP)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.

Young-Jun Park (YJ)

Department of Biochemistry, University of Washington, Seattle, WA, USA.

Joost Snijder (J)

Department of Biochemistry, University of Washington, Seattle, WA, USA.
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.

Sofia Cheliout Da Silva (SC)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.

Bang Vu (B)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.

Lianying Yan (L)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.

Yan-Ru Feng (YR)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.

Barry Rockx (B)

Sealy Center for Vaccine Development, Departments of Pathology and Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX, USA.
Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.

Thomas W Geisbert (TW)

Sealy Center for Vaccine Development, Departments of Pathology and Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX, USA.

Chad E Mire (CE)

Sealy Center for Vaccine Development, Departments of Pathology and Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX, USA.

Christopher C Broder (CC)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA. christopher.broder@usuhs.edu.
ORCID: 0000-0001-5382-0510

David Veesler (D)

Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.
ORCID: 0000-0002-6019-8675

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › An antibody against the F glycoprotein...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › An antibody against the F glycoprotein...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › An antibody against the F glycoprotein...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › An antibody against the F glycoprotein...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › An antibody against the F glycoprotein...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Mononegavirales › Paramyxoviridae › Paramyxovirinae › Henipavirus › Virus Hendra › An antibody against the F glycoprotein...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Mononegavirales › Infections à Paramyxoviridae › Infections à hénipavirus › An antibody against the F glycoprotein...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › An antibody against the F glycoprotein...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles moléculaires › An antibody against the F glycoprotein...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Mononegavirales › Paramyxoviridae › Paramyxovirinae › Henipavirus › Virus Nipah › An antibody against the F glycoprotein...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › An antibody against the F glycoprotein...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Pénétration virale › An antibody against the F glycoprotein...